Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

PhytoMedical enters CRADA to synthesize type 2 diabetes compounds

Dec. 10, 2004

Orally active cathepsin inhibitor effective against osteoporosis in vivo

Dec. 10, 2004

DHEA shows promise in the management of abdominal obesity

Dec. 9, 2004

Novel tetrahydroisoquinoline derivatives show insulin-sensitizing effects with fewer side effects

Dec. 9, 2004

New RXR antagonists in early development at Novartis for diabetes and diabetic complications

Dec. 7, 2004

Putative metabolites of rosiglitazone described in a patent

Dec. 7, 2004

Phase I data suggest a favorable safety profile for APD-356 in obese subjects

Dec. 7, 2004

Syrrx researchers report DPP4 inhibitors

Dec. 3, 2004

Taisho and Arena Pharmaceuticals jointly patent MCH receptor antagonists

Dec. 3, 2004

Intrinsa: potential risks outweigh sexual benefits

Dec. 3, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Recludix’s first-in-class STAT6 inhibitor shows efficacy in atopic dermatitis
BioWorld Science
Researchers from Recludix Pharma Inc. reported preclinical efficacy data on REX-8756 (SAR-448755), a first-in-class orthosteric STAT6 inhibitor in models of...